비교리스트

 카트 문의
시장보고서
상품코드
1625398

비알코올성 지방간염 치료 시장 규모, 점유율, 동향, 산업 분석 보고서 : 약제별, 단계별, 유통 채널별, 지역별 - 시장 예측(2025-2034년)

Non-alcoholic Steatohepatitis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 128 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최근 조사에 따르면 비알코올성 지방간염(NASH) 치료 시장 규모는 2034년까지 909억 7,000만 달러에 이를 것으로 예상됩니다. 이 보고서는 현재 시장 역학을 상세하게 통찰하고 미래 시장 성장에 대한 분석을 제공합니다.

비알코올성 지방간염(NASH) 치료 시장의 성장은 NASH의 개척과 강하게 연관된 비만, 2형 당뇨병, 대사 증후군과 같은 위험 인자의 유병률 증가에 기인합니다. 세계에서 NASH의 유병률이 상승하고 있기 때문에 제약 기업에 충분한 시장 기회가 창출될 것으로 기대되고 있습니다.

NASH 치료 시장은 간염, 섬유화, 인슐린 저항성을 포함한 NASH의 복잡한 병태 생리를 표적으로 한 연구 노력과 혁신적인 치료법 증가로 강력한 성장 궤도를 타는 것으로 예상됩니다. NASH 치료 시장 규모는 북미, 유럽, 아시아태평양 등 지역을 중심으로 세계 NASH 이환율의 상승이 계속되고 있기 때문에 확대 경향에 있습니다.

비알코올성 지방간염 치료 시장 전망은 낙관적이며 오베티콜산(OCA), 세마글루티드, 라니피브라놀, 비타민E 등 임상시험을 진행하고 규제 당국의 승인을 얻은 치료제의 수가 증가하고 있습니다. 건강 관리에 대한 접근성 확대, NASH에 대한 의식 증가, 간 질환에 대한 관심 증가는 NASH 치료에 대한 수요 증가에 기여합니다. 게다가, 특히 선진국에서는 고령화가 진행되고 있으며 혁신적인 치료법의 필요성이 높아지고 있습니다. 진단 및 치료 옵션의 진보는 의료 산업의 이해 관계자에게 큰 성장 가능성과 기회를 제공하고 상당한 확장을 촉진하도록 설정되어 있습니다.

비알코올성 지방간염 치료 시장 보고서 하이라이트

약물별로는 2024년 비타민E와 피오글리타존 부문이 비알코올성 지방간염(NASH) 치료 시장 수익의 최대 점유율을 차지했는데, 이는 NASH 환자의 간염 억제와 인슐린 감수성 개선에 대한 효능이 확립되었습니다.

유통 채널을 기반으로 한 소매 및 전문 약국 시스템 분야는 접근하기 쉽고 NASH 치료를 위한 전문 약물 및 환자 지원을 제공할 수 있기 때문에 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예상됩니다.

2024년에는 북미가 비알코올성 지방간염 치료 시장 점유율을 독점했는데, 이는 비만과 2형 당뇨병의 유병률이 높고 강력한 건강 관리 인프라와 간 질환 관리에 대한 많은 투자 때문입니다.

아시아태평양 시장은 건강 관리 지출 증가와 간 질환 관리에 대한 의식 증가로 예측 기간 동안 큰 성장이 예상됩니다.

세계 주요 시장 진출 기업은 Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc(Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk Bristol-Myers Squibb Company; and Gilead Sciences, Inc. 등입니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 비알코올성 지방간염 치료 시장 인사이트

  • 시장 현황
  • 비알코올성 지방간염 치료 시장 역학
    • 성장 촉진요인과 기회
      • 고령화 인구 증가
      • 2형 당뇨병의 발병률 상승
    • 성장 억제요인과 과제
      • 고액의 치료비
  • PESTEL 분석
  • 비알코올성 지방간염 치료 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 비알코올성 지방간염 치료 시장 : 약제별

  • 주요 조사 결과
  • 소개
  • 비타민E와 피오글리타존
  • 오베티콜산(OCA)
  • 라니피브라놀
  • 세마글루티드
  • 레스메티롬
  • Aramchol
  • 세니크리비록
  • 기타 약

제6장 세계의 비알코올성 지방간염 치료 시장 : 단계별

  • 주요 조사 결과
  • 소개
  • NASH 스테이지 F0
  • NASH 스테이지 F1
  • NASH 스테이지 F2
  • NASH 스테이지 F3
  • NASH 스테이지 F4

제7장 세계의 비알코올성 지방간염 치료 시장 : 유통 채널별

  • 주요 조사 결과
  • 소개
  • 병원 약국
  • 소매 및 전문 약국
  • 기타 약국

제8장 세계의 비알코올성 지방간염 치료 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 비알코올성 지방간염 치료 시장 평가 : 지역별(2020-2034년)
  • 북미
    • 북미 : 약제별(2020-2034년)
    • 북미 : 질환 스테이지별(2020-2034년)
    • 북미 : 유통 채널별(2020-2034년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 약제별(2020-2034년)
    • 유럽 : 질환 스테이지별(2020-2034년)
    • 유럽 : 유통 채널별(2020-2034년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 약제별(2020-2034년)
    • 아시아태평양 : 질환 스테이지별(2020-2034년)
    • 아시아태평양 : 유통 채널별(2020-2034년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 약제별(2020-2034년)
    • 중동 및 아프리카 : 질환 스테이지별(2020-2034년)
    • 중동 및 아프리카 : 유통 채널별(2020-2034년)
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 약제별(2020-2034년)
    • 라틴아메리카 : 질환 스테이지별(2020-2034년)
    • 라틴아메리카 : 유통 채널별(2020-2034년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확장 및 인수 분석
    • 확장
    • 인수
  • 파트너십/협업/계약/공개

제10장 기업 프로파일

  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd
  • Inventiva
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc.(Madrigal)
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
KTH 25.02.03

The non-alcoholic steatohepatitis treatment market size is expected to reach USD 90.97 billion by 2034, according to a new study by Polaris Market Research. The report "Non-alcoholic Steatohepatitis Treatment Market Share, Size, Trends, Industry Analysis Report: By Drug, Disease Stage, Distribution Channel (Hospital Pharmacies, Retail and Specialty Pharmacies, and Other Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The non-alcoholic steatohepatitis (NASH) treatment market growth is attributed to the rising prevalence of risk factors such as obesity, type 2 diabetes, and metabolic syndrome, strongly linked to the development of NASH. The rising prevalence of NASH across the world is expected to create ample market opportunities for pharmaceutical companies.

The NASH treatment market is expected to experience a robust growth trajectory, increasing research efforts and innovative therapies targeting the complex pathophysiology of NASH, including liver inflammation, fibrosis, and insulin resistance. The market size for NASH treatments is expanding, with the global incidence of NASH continuing to rise, particularly in regions such as North America, Europe, and Asia Pacific.

The non-alcoholic steatohepatitis treatment market outlook is optimistic, with a growing number of drugs, including Obeticholic Acid (OCA), Semaglutide, Lanifibranor, and Vitamin E, advancing through clinical trials and receiving regulatory approvals. The expansion of healthcare access, increased awareness about NASH, and the growing focus on liver diseases contribute to the rising demand for NASH treatments. Moreover, the aging population, especially in developed countries, accelerates the need for innovative therapies. Advancements in diagnostics and treatment options are set to drive significant expansion, offering considerable growth potential and opportunities for stakeholders within the healthcare industry.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights

In terms of drug, in 2024, the vitamin E and pioglitazone segment accounted for the largest share of the non-alcoholic steatohepatitis (NASH) treatment market revenue due to its well-established efficacy in reducing liver inflammation and improving insulin sensitivity in NASH patients.

The retail and specialty pharmacies systems segment, based on distribution channel, is expected to witness the highest CAGR during the forecast period due to its accessibility and ability to provide specialized medications and patient support for NASH treatment.

In 2024, North America dominated the non-alcoholic steatohepatitis treatment market share due to the high prevalence of obesity and type 2 diabetes, coupled with strong healthcare infrastructure and substantial investment in liver disease research.

The Asia Pacific market is expected to witness significant growth during the forecast period due to increasing healthcare expenditure and greater awareness of liver disease management.

A few global key market players are Intercept Pharmaceuticals, Inc.; Galmed Pharmaceuticals Ltd; Inventiva; AbbVie Inc.; Galectin Therapeutics Inc.; Madrigal Pharmaceuticals Inc (Madrigal); NGM Biopharmaceuticals, Inc.; Novo Nordisk A/S; The Bristol-Myers Squibb Company; and Gilead Sciences, Inc.

Polaris Market Research has segmented the non-alcoholic steatohepatitis treatment market report on the basis of drug, disease stage, distribution channel, and region:

By Drug Outlook (Revenue, USD Billion; 2020-2034)

  • Vitamin E and Pioglitazone
  • Obeticholic Acid (OCA)
  • Lanifibranor
  • Semaglutide
  • Resmetirom
  • Aramchol
  • Cenicriviroc
  • Other Drugs

By Disease Stage Outlook (Revenue, USD Billion; 2020-2034)

  • NASH Stage F0
  • NASH Stage F1
  • NASH Stage F2
  • NASH Stage F3
  • NASH Stage F4

By Distribution Channel Outlook (Revenue, USD Billion; 2020-2034)

  • Hospital Pharmacies
  • Retail and Specialty Pharmacies
  • Other Pharmacies

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-alcoholic Steatohepatitis Treatment Market Insights

  • 4.1. Non-alcoholic Steatohepatitis Treatment Market - Market Snapshot
  • 4.2. Non-alcoholic Steatohepatitis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Aging Population
      • 4.2.1.2. Rising Incidence of Type 2 Diabetes
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-alcoholic Steatohepatitis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
  • 5.3. Vitamin E and Pioglitazone
    • 5.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Vitamin E and Pioglitazone, by Region, 2020-2034 (USD Billion)
  • 5.4. Obeticholic Acid (OCA)
    • 5.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Obeticholic Acid (OCA), by Region, 2020-2034 (USD Billion)
  • 5.5. Lanifibranor
    • 5.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Lanifibranor, by Region, 2020-2034 (USD Billion)
  • 5.6. Semaglutide
    • 5.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Semaglutide, by Region, 2020-2034 (USD Billion)
  • 5.7. Resmetirom
    • 5.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Resmetirom, by Region, 2020-2034 (USD Billion)
  • 5.8. Aramchol
    • 5.8.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Aramchol, by Region, 2020-2034 (USD Billion)
  • 5.9. Cenicriviroc
    • 5.9.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Cenicriviroc, by Region, 2020-2034 (USD Billion)
  • 5.10. Other Drugs
    • 5.10.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Drugs, by Region, 2020-2034 (USD Billion)

6. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
  • 6.3. NASH Stage F0
    • 6.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F0, by Region, 2020-2034 (USD Billion)
  • 6.4. NASH Stage F1
    • 6.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F1, by Region, 2020-2034 (USD Billion)
  • 6.5. NASH Stage F2
    • 6.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F2, by Region, 2020-2034 (USD Billion)
  • 6.6. NASH Stage F3
    • 6.6.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F3, by Region, 2020-2034 (USD Billion)
  • 6.7. NASH Stage F4
    • 6.7.1. Global Non-alcoholic Steatohepatitis Treatment Market, by NASH Stage F4, by Region, 2020-2034 (USD Billion)

7. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.4. Retail and Specialty Pharmacies
    • 7.4.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Retail and Specialty Pharmacies, by Region, 2020-2034 (USD Billion)
  • 7.5. Other Pharmacies
    • 7.5.1. Global Non-alcoholic Steatohepatitis Treatment Market, by Other Pharmacies, by Region, 2020-2034 (USD Billion)

8. Global Non-alcoholic Steatohepatitis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-alcoholic Steatohepatitis Treatment Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-alcoholic Steatohepatitis Treatment Market - North America
    • 8.3.1. North America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.4. Non-alcoholic Steatohepatitis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.4.2. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.4.3. U.S.: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.3.5. Non-alcoholic Steatohepatitis Treatment Market - Canada
      • 8.3.5.1. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.4. Non-alcoholic Steatohepatitis Treatment Market - Europe
    • 8.4.1. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.4. Non-alcoholic Steatohepatitis Treatment Market - UK
      • 8.4.4.1. UK: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.5. Non-alcoholic Steatohepatitis Treatment Market - France
      • 8.4.5.1. France: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.6. Non-alcoholic Steatohepatitis Treatment Market - Germany
      • 8.4.6.1. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.7. Non-alcoholic Steatohepatitis Treatment Market - Italy
      • 8.4.7.1. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.8. Non-alcoholic Steatohepatitis Treatment Market - Spain
      • 8.4.8.1. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.9. Non-alcoholic Steatohepatitis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.10. Non-alcoholic Steatohepatitis Treatment Market - Russia
      • 8.4.10.1. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.4.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.5. Non-alcoholic Steatohepatitis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.4. Non-alcoholic Steatohepatitis Treatment Market - China
      • 8.5.4.1. China: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.5. Non-alcoholic Steatohepatitis Treatment Market - India
      • 8.5.5.1. India: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.6. Non-alcoholic Steatohepatitis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.7. Non-alcoholic Steatohepatitis Treatment Market - Japan
      • 8.5.7.1. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.8. Non-alcoholic Steatohepatitis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.9. Non-alcoholic Steatohepatitis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.10. Non-alcoholic Steatohepatitis Treatment Market - Australia
      • 8.5.10.1. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.5.11. Non-alcoholic Steatohepatitis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.6. Non-alcoholic Steatohepatitis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.4. Non-alcoholic Steatohepatitis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.5. Non-alcoholic Steatohepatitis Treatment Market - UAE
      • 8.6.5.1. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.6. Non-alcoholic Steatohepatitis Treatment Market - Israel
      • 8.6.6.1. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.7. Non-alcoholic Steatohepatitis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.6.8. Non-alcoholic Steatohepatitis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 8.7. Non-alcoholic Steatohepatitis Treatment Market - Latin America
    • 8.7.1. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.4. Non-alcoholic Steatohepatitis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.5. Non-alcoholic Steatohepatitis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.6. Non-alcoholic Steatohepatitis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 8.7.7. Non-alcoholic Steatohepatitis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Drug, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Disease Stage, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-alcoholic Steatohepatitis Treatment Market, by Distribution Channel, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Intercept Pharmaceuticals, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Galmed Pharmaceuticals Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Inventiva
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. AbbVie Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Galectin Therapeutics Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Madrigal Pharmaceuticals Inc. (Madrigal)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. NGM Biopharmaceuticals, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Novo Nordisk A/S
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. The Bristol-Myers Squibb Company
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Gilead Sciences, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제